Use of Systemic Corticosteroids for Atopic Dermatitis Use of Systemic Corticosteroids for Atopic Dermatitis

Despite recommendations against the use of systemic corticosteroids for atopic dermatitis, their use remains widespread. Under what limited circumstances is it appropriate to use them?The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Related Links:

CONCLUSION: Preliminary results demonstrate that oral small molecules are an effective treatment option in AD with minimal side effects. Additional randomized studies with larger sample sizes are needed to determine the efficacy and long-term side effects of these novel therapies. PMID: 30501539 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Condition:   Atopic Dermatitis Interventions:   Drug: Tralokinumab;   Other: Placebo Sponsor:   LEO Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In conclusion, a drastic increase in microbial diversity and decrease in S. aureus proportion were observed with eczema treatment. Narrowband ultraviolet B treatment did not exert additive effects on eczema improvement; however, it appeared to reduce the recurrence of eczema. PMID: 30460369 [PubMed - as supplied by publisher]
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research
Conclusion: Systemic and airway type 2 inflammatory biomarkers remain elevated in OCS-dependent severe asthma pts. DPL improved FEV1 and showed rapid and sustained suppression of biomarkers despite larger OCS reduction, and was generally well tolerated.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Allergy and immunology Source Type: research
Conclusions: In the CAR registry, patients with SAA treated with omalizumab showed a significant positive effect of anti-IgE therapy not only on the asthma control, but also on allergic comorbidities. PMID: 30429711 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
A 37 ‐year‐old woman with a history of mild atopic dermatitis involving her antecubital flexures and sporadically her face presented with face eczema of one year duration. Due to acne and solar brown spots, she had applied a retinoic acid containing cream for one year and she had slowly developed rec alcitrant face eczema that was unsuccessfully treated with different moisturizing creams, corticosteroid creams and sunscreens. As her face eczema further worsened the patient was referred for patch testing.
Source: Contact Dermatitis - Category: Dermatology Authors: Tags: CONTACT POINT Source Type: research
Discussion Hypopigmentation can be worrisome for many families because of cosmesis and the worry that “something is wrong.” The normal natural changes in skin-tone over the year due to different light exposure and wide variations within individuals is not something that many people are aware of. Post-inflammatory hypopigmentation is a common cause of hypopigmentation. Vitiligo is the most common cause of depigmentation. Vitiligo is an acquired, depigmenting disorder with typical lesions appearing as milky white macules with distinct margins that are not scaly. Hair (including eyebrows and eyelashes) can be dep...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
Authors: Md S, Kuldeep Singh JKA, Waqas M, Pandey M, Choudhury H, Habib H, Hussain F, Hussain Z Abstract Betamethsone valerate (BMV), a medium potency topical corticosteroid, is one of the most commonly employed pharmacological agents for the management of atopic dermatitis (AD) in both adults and children. Despite having remarkable pharmacological efficacy, these agents have limited clinical implication due to poor penetration across the startum cornum (SC). To mitigate issues related to targeted delivery, stability, and solubility as well as to potentiate therapeutic and clinical implication, the nanodelivery sys...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Condition:   Atopic Dermatitis Interventions:   Drug: Baricitinib;   Drug: Topical corticosteroid;   Drug: Placebo Sponsors:   Eli Lilly and Company;   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Corticosteroid Therapy | Dermatitis | Dermatology | Health | Skin | UK Health